Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

The exact connection between Alzheimer's disease (AD) and type 2 diabetes is still in
debate. However, poorly controlled blood sugar may increase the risk of developing …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Therapeutic strategies for neurodegenerative disorders have commonly targeted individual
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …

Abstract Insulin-like growth factor-1 (IGF-1), a pleiotropic polypeptide, plays an essential role
in CNS development and maturation. Glucagon-like peptide-1 (GLP-1) is an endogenous …

Introduction: This review evaluates the novel strategy of treating Alzheimer's and Parkinson's
disease (AD and PD) withdrugs that initially have been developed to treat type 2 diabetes …

Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been
identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's …

Among the more promising treatments proposed for Alzheimer's disease (AD) and
Parkinson's disease (PD) are those reducing brain insulin resistance. The antidiabetics in …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

Diabetes mellitus (DM) is a gradually rising metabolic disease which is currently affecting
millions of people worldwide. Diabetes is associated with various complications like …